GLP-1 drugs cut heart attack risk by 22% vs competitors, but may increase vision loss risk

Key Findings

👁️ GLP-1 drugs linked to 70% higher risk of rare vision loss condition

• Meta-analysis of 15 studies covering over 1.5 million patients found GLP-1 receptor agonists associated with 70% higher odds of non-arteritic ischemic optic neuropathy (NAION)

• Absolute risk remained very low at 0.09% in GLP-1 users, meaning about 1 in 2,700 patients might experience this vision-threatening condition

• The condition causes sudden, permanent vision loss in one or both eyes and has no effective treatment

🧠 Semaglutide may protect against brain bleeds in people with aneurysms

• Among 4,550 people with brain aneurysms and diabetes, those taking GLP-1 drugs had 34% lower risk of subarachnoid hemorrhage (brain bleeding) over 5 years

• The drugs were also associated with 37% lower risk of death from any cause in this high-risk population

• Brain aneurysm rupture is often fatal, so even modest protection could be clinically meaningful

🚶‍♂️ GLP-1 drugs improve walking distance and reduce amputations in diabetes patients

• Meta-analysis of 7 studies with 107,092 participants found GLP-1 drugs improved functional walking distance by 10% in people with diabetes and peripheral artery disease

• Risk of lower leg amputation dropped by 47%, with the strongest protection from tirzepatide (55% reduction) and semaglutide (54% reduction)

• 82.5% of patients achieved meaningful weight loss of 5% or more, compared to 0% on placebo

🫁 Tirzepatide cuts sleep apnea severity and heart failure hospitalizations

• In obesity-related sleep apnea patients, tirzepatide reduced apnea-hypopnea index (breathing interruptions per hour) alongside significant weight loss

• The drug also decreased heart failure hospitalizations in patients with preserved ejection fraction

• Improvements occurred through both weight loss and direct metabolic effects on inflammation and cardiovascular function

🧬 New cAMP-biased GLP-1 drug maintains blood sugar control with less nausea

• Ecnoglutide, engineered to favor specific cellular signaling pathways, reduced HbA1c by 1.96-2.43% in 211 Chinese patients with type 2 diabetes

• Animal studies showed the modified drug caused fewer episodes of vomiting in shrews and less nausea-like behavior in rats compared to standard GLP-1 drugs

• The approach maintains glucose benefits while potentially reducing the gastrointestinal side effects that cause many patients to stop treatment

🍽️ Most GLP-1 studies ignore what patients actually eat, creating knowledge gap

• Systematic review of 41 randomized trials found only 2 studies (5%) actually measured dietary changes in patients taking liraglutide, semaglutide, or tirzepatide

• The two studies that did track food intake found 24-39% reductions in total calories consumed, but most research focuses only on weight and blood sugar

• This gap means doctors don't know how these drugs change eating patterns, nutrient intake, or long-term dietary quality